Opinion|Videos|July 10, 2024
Key Financial Factors Associated With Typical PNH Treatment Journey
Dr Haumschild and a panel of medical experts underscore financial considerations in PNH treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please walk us through the typical patient journey for individuals with PNH, highlighting the key touchpoints, challenges, and unmet needs encountered along the way.
- What challenges, beyond coverage approval, have you faced in ensuring seamless access to PNH medications for patients, and how do financial factors impact your treatment decisions?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
5